XO
XOMA Royalty Corporation
XOMAP · NASDAQ
$24.98 +0.00% (+$0.00)
Market Cap $301.3M
P/E Ratio 9.50x
Div. Yield 8.63%
ROE 31.88%
Bulios Fair Price
$35.07
40.4% upside
Current Price
$24.98
Undervalued Fair Value Overvalued
According to Bulios Fair Price, XOMAP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
35 /100
Fair P/E 9.50x
P/B 2.90x
EV/EBITDA 24.38x
Growth
78 /100
Growing Rev. growth 105.30%
Book val. growth 5.71%
EPS growth N/A
Profitability
79 /100
Strong Gross margin 94.32%
FCF margin 5.51%
Net margin 60.81%
Quality
56 /100
Average ROIC 4.49%
Asset turnover 0.19x
ROE 31.88%
Debt
42 /100
Moderate Debt/Equity 1.27x
Net debt/EBITDA 3.39x
Current ratio 3.37x
Stability
28 /100
Unstable Beta 0.87x
Profitable years 1
Rev. volatility 275.01%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about XOMAP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Owen Patrick Hughes
Employees
14
Headquarters
Emeryville